GW Henssler & Associates Ltd. Purchases 1,183 Shares of Merck & Co., Inc. (NYSE:MRK)

by · The Cerbat Gem

GW Henssler & Associates Ltd. boosted its position in Merck & Co., Inc. (NYSE:MRK – Free Report) by 0.7% in the third quarter, HoldingsChannel reports. The firm owned 165,119 shares of the company’s stock after buying an additional 1,183 shares during the quarter. GW Henssler & Associates Ltd.’s holdings in Merck & Co., Inc. were worth $18,751,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. Itau Unibanco Holding S.A. bought a new position in Merck & Co., Inc. in the 2nd quarter valued at $39,000. Abich Financial Wealth Management LLC increased its stake in shares of Merck & Co., Inc. by 121.8% during the 2nd quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock worth $40,000 after purchasing an additional 179 shares during the last quarter. Quarry LP purchased a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth approximately $42,000. Strategic Financial Concepts LLC lifted its stake in Merck & Co., Inc. by 1,475.6% in the second quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock valued at $43,000 after purchasing an additional 32,832 shares during the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC grew its holdings in Merck & Co., Inc. by 47.5% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 379 shares of the company’s stock valued at $43,000 after purchasing an additional 122 shares during the period. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Up 0.3 %

Shares of NYSE:MRK traded up $0.29 during midday trading on Tuesday, hitting $104.52. 2,195,502 shares of the stock traded hands, compared to its average volume of 8,755,150. Merck & Co., Inc. has a one year low of $99.80 and a one year high of $134.63. The stock has a market capitalization of $264.73 billion, a PE ratio of 19.39, a P/E/G ratio of 1.49 and a beta of 0.39. The company has a quick ratio of 1.22, a current ratio of 1.47 and a debt-to-equity ratio of 0.80. The business’s 50 day moving average is $113.32 and its two-hundred day moving average is $121.44.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $2.28 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.12. Merck & Co., Inc. had a return on equity of 40.69% and a net margin of 21.99%. The company had revenue of $16.10 billion during the quarter, compared to analyst estimates of $15.87 billion. During the same quarter last year, the firm posted ($2.06) earnings per share. The firm’s revenue was up 7.1% on a year-over-year basis. As a group, research analysts forecast that Merck & Co., Inc. will post 7.76 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Bank of America decreased their price objective on Merck & Co., Inc. from $150.00 to $145.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 target price on shares of Merck & Co., Inc. in a report on Thursday, October 3rd. Morgan Stanley lifted their price target on Merck & Co., Inc. from $132.00 to $134.00 and gave the company an “equal weight” rating in a research report on Thursday, July 11th. Barclays cut their target price on Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating for the company in a research note on Monday, October 7th. Finally, Wells Fargo & Company lowered their price target on shares of Merck & Co., Inc. from $140.00 to $125.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have assigned a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $131.46.

Check Out Our Latest Research Report on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).